Tellgen(SZ:300642)2020-04-24 16:00Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2019, representing a year-on-year growth of 25% compared to 2018[13]. - The net profit attributable to shareholders was RMB 300 million, an increase of 30% from the previous year[13]. - The company's operating revenue for 2019 was CNY 441,452,526.03, representing a year-on-year increase of 21.00% compared to CNY 364,846,388.39 in 2018[18]. - The net profit attributable to shareholders for 2019 was CNY 157,018,318.31, which is a 10.82% increase from CNY 141,690,851.93 in 2018[18]. - The net profit after deducting non-recurring gains and losses was CNY 142,483,050.69, up 18.20% from CNY 120,540,224.16 in 2018[18]. - The company achieved a basic earnings per share of CNY 1.740 in 2019, reflecting a growth of 10.69% from CNY 1.572 in 2018[18]. - The company achieved operating revenue of 441.45 million yuan, with reagent revenue accounting for 94.04% at 415.12 million yuan, representing a year-on-year growth of 19.48%[38]. - The company achieved a revenue of CNY 441.45 million in 2019, representing a year-on-year growth of 21.00%[54]. - Net profit for the year was CNY 157.02 million, an increase of 10.82% compared to the previous year[54]. Dividend Policy - The company plans to distribute a cash dividend of RMB 4 per 10 shares, totaling approximately RMB 36.33 million[5]. - The company has established a cash dividend policy, aiming for a minimum of 20% of distributable profits to be distributed as cash dividends annually over the next three years[126]. - The cash dividend for 2018 was RMB 3.0 per 10 shares, amounting to RMB 27,252,045.00, with a total share capital of 90,840,150 shares[138]. - The cash dividend for 2017 was RMB 4.0 per 10 shares, totaling RMB 24,224,840.00, based on a total share capital of 60,562,100 shares[138]. - The cash dividends for 2019, 2018, and 2017 represented 23.13%, 19.23%, and 19.10% of the net profit attributable to ordinary shareholders, respectively[140]. - The company’s cash dividend policy is in compliance with its articles of association and shareholder resolutions[134]. Market Expansion and Strategy - The company aims to expand its market presence in Southeast Asia, targeting a 20% market share by 2022[13]. - The management provided a performance guidance for 2020, projecting a revenue growth of 20% to 30%[13]. - The company is focused on developing clinical detection solutions for tumor markers, utilizing high-throughput fluorescence technology and chemiluminescence immunoassay technology[27]. - The company is committed to enhancing communication with pricing authorities and medical institutions to expedite the market entry of innovative products[116]. - The company aims to enhance its product offerings beyond tumor detection to include autoimmune diseases, infections, cardiovascular, and thyroid conditions, thereby increasing its market share[111]. - The company intends to deepen market penetration by deploying sales forces in lower-tier cities as part of its "precision market" initiative[112]. Research and Development - The company is investing RMB 100 million in R&D for innovative diagnostic solutions, with a focus on cancer biomarkers and infectious diseases[13]. - R&D investment reached CNY 51.99 million, accounting for 11.78% of the company's revenue during the reporting period[48]. - The company has a total of 110 ongoing R&D projects across various fields, ensuring a robust pipeline for future product launches[48]. - The company has developed multiple innovative products, including the first domestic flow cytometry detection product and the first medical device for Y chromosome microdeletion detection[45]. - The company is actively involved in the development of diagnostic kits for various viral infections and tumor markers[81]. - The company plans to invest more in R&D, focusing on four technology platforms: biochemistry, immunology, molecular diagnostics, and mass spectrometry[112]. Product Development and Innovation - New product launches in 2020 are expected to contribute an additional RMB 200 million in revenue, focusing on high-throughput diagnostic technologies[13]. - The company has developed a series of HPV detection products based on high-throughput flow fluorescence technology, providing comprehensive solutions for HPV nucleic acid testing[29]. - The company has developed the SHOX2 and RASSF1A gene methylation DNA testing kits, which are the first domestic products for lung cancer methylation detection, aiding in the diagnosis of suspected lung cancer patients[29]. - The company has developed a series of products for the clinical auxiliary diagnosis of personalized medicine, including mutation detection kits for key genes such as EGFR and K-ras[29]. - The company launched multiple diagnostic kits, including the CA72-4 and CA242 test kits, aimed at quantifying tumor markers in human serum[82]. - The company introduced a multi-tumor marker quality control product to evaluate the precision of tumor marker detection tests and laboratory processes[82]. Risk Management - The company faces potential risks related to regulatory changes and market competition, which it plans to mitigate through strategic partnerships and innovation[5]. - The ongoing COVID-19 pandemic poses a significant risk to the company's first-quarter performance due to reduced testing volumes from its main clients[113]. - The company is experiencing a decline in product gross margin due to increased competition and rising costs, prompting efforts to optimize production processes and introduce more competitive products[117]. - The company has implemented measures to prevent core technology leakage, including signing confidentiality agreements and non-compete contracts with key technical personnel[115]. - The company faces risks related to new product development and registration, as successful product development requires passing clinical trials and obtaining regulatory approval[116]. Operational Efficiency - The company has established a strict quality management system in accordance with ISO13485:2016 standards to ensure product quality meets regulatory and user requirements[35]. - The company has constructed cleanrooms and established strict production control procedures, complying with relevant safety and quality regulations[62]. - The company has implemented a comprehensive employee welfare system, including social security and health insurance, to ensure employee well-being[177]. - The company has not engaged in any major related party transactions during the reporting period, including daily operations, asset acquisitions, or joint investments[164][165][166]. Shareholder Relations - The company provided opportunities for minority shareholders to express their opinions and ensured their rights were protected[135]. - The independent directors confirmed their responsibilities were fulfilled regarding the cash dividend proposals[135]. - The company has a commitment to timely and accurately fulfill information disclosure obligations according to stock exchange rules[142]. - The company has a policy that allows for a maximum annual transfer of 25% of shares held during the tenure of the shareholders[142]. Compliance and Governance - The company strictly adhered to environmental protection laws and regulations, with no violations reported during the reporting period[180]. - The company maintains a robust internal control system and governance structure, ensuring timely and accurate information disclosure to shareholders[176]. - The company made changes to its accounting policies in accordance with the latest regulations from the Ministry of Finance, which did not affect total assets, net assets, or net profit[148]. - The company appointed Lixin Accounting Firm as its auditor, with an audit fee of 600,000 RMB, and has maintained this auditor for 8 years[154].